Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Curis | CRIS | Mar 12, 2025 | 2.63 | -1.13 |
CURRENC Group | CURR | Mar 12, 2025 | 2.99 | +7.55 |
Curtiss-Wright | CW | Mar 12, 2025 | 314.15 | +1.00 |
Cushing Mlp & Infrastructure Total Return Fund | SRV | Mar 12, 2025 | 43.48 | +2.47 |
Cushman & Wakefield | CWK | Mar 12, 2025 | 11.24 | +0.72 |
Custom Truck One Source | CTOS | Mar 12, 2025 | 4.77 | -2.85 |
Customers Bancorp | CUBI | Mar 12, 2025 | 49.81 | +3.34 |
Customers Bancorp E Pref | CUBI-E | Mar 12, 2025 | 25.62 | -0.43 |
Customers Bancorp F Pref | CUBI-F | Mar 12, 2025 | 25.40 | 0.00 |
Cutera | CUTR | Mar 12, 2025 | 0.11 | 0.00 |
CVB Financial | CVBF | Mar 12, 2025 | 18.60 | +0.27 |
CVD Equipment | CVV | Mar 12, 2025 | 3.00 | 0.00 |
CVR Energy | CVI | Mar 12, 2025 | 17.97 | +0.06 |
Cvr Partners LP Unit | UAN | Mar 12, 2025 | 74.78 | -0.08 |
CVRx | CVRX | Mar 12, 2025 | 11.63 | +0.61 |
CVS Health | CVS | Mar 12, 2025 | 64.84 | -0.22 |
CXApp A | CXAI | Mar 12, 2025 | 0.99 | +4.32 |
CyberArk Software | CYBR | Mar 12, 2025 | 338.49 | +2.28 |
Cybin | CYBN | Mar 12, 2025 | 7.34 | +2.66 |
Cyclacel Pharmaceuticals | CYCC | Mar 12, 2025 | 0.30 | -3.33 |
Cyclacel Pharmaceuticals Pref | CYCCP | Mar 12, 2025 | 5.77 | +4.91 |
Cyclerion Therapeutics | CYCN | Mar 12, 2025 | 2.55 | -0.58 |
Cyclo Therapeutics | CYTH | Mar 12, 2025 | 0.67 | -0.50 |
Cycurion | CYCU | Mar 12, 2025 | 0.54 | 0.00 |
Cyngn | CYN | Mar 12, 2025 | 4.38 | +14.36 |
Cytek Biosciences | CTKB | Mar 12, 2025 | 4.17 | -2.57 |
Cytokinetics | CYTK | Mar 12, 2025 | 43.99 | -0.92 |
Cytomed Therapeutics | GDTC | Mar 12, 2025 | 2.60 | -0.76 |
CytomX Therapeutics | CTMX | Mar 12, 2025 | 0.60 | -3.48 |
Cytosorbents | CTSO | Mar 12, 2025 | 1.07 | +7.00 |
|
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.